


INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Docket Number ALT-006US1 (1009/007)		Application Number 09/779,439	
				Applicant Antoine Noujaim			
				Filing Date February 8, 2002		Group Art Unit 2152	
Sheet	1	OF	1				

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

Foreign Patent Documents							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)			
LAB	A1	Schultz, Birgit C. et al., <i>Cancer Immunol.</i> , "Anti-idiotype therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1)", 46:201-212, 1998.	
	A2	Madiyalakan, R. et al., <i>HYBRIDOMA</i> , "Antiidiotype Induction Therapy: Evidence for the Induction of Immune Response Through the Idiotype Network in Patients With Ovarian Cancer After Administration of Anti-CA125 Murine Monoclonal Antibody B43.13", 14:199-203, 1995.	
	A3	Reinhartz, S. et al., <i>HYBRIDOMA</i> , "Evaluation of Immunological Responses in Patients with Ovarian Cancer Treated with the Anti-idiotype Vaccine ACA125 by Determination of Intracellular Cytokines—A Preliminary Report", 18:41-45, 1999.	
	A4	Schlebusch, Harald, et al., <i>HYBRIDOMA</i> , "A Monoclonal Antiidiotypic Antibody ACA 125 Mimicking the Tumor-Associated Antigen CA 125 for Immunotherapy of Ovarian Cancer", 14:167-174, 1995.	
	A5	Kohler, S. et al., <i>Gynakologische Tumoren</i> , "Ammuntherapie des Ovarial-karzinoms mit dem monoklonalen anti-idiotypischen Antikörper ACA 125-Ergebnisse der Phase-ib-Studie", 58:180-186, 1998.	
	A6	Leveugle, B. et al., XP-002194280 (#2424), "PSA-directed Immunotherapy of Prostate Cancer".	
LAB	A7	Wagner, Uwe A. et al., <i>Biotechnology Therapeutics</i> , "Immunotherapy of Advanced Ovarian Carcinomas by Activation of the idiotypic Network", 3:81-89, 1992.	
	A8		
	A9		
	B1		

EXAMINER /Lynn Bristol/	DATE CONSIDERED 11/05/2006
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/824554
				Filing Date	April 14, 2004
				First Named Inventor	Ragupathy Madiyalakan
				Art Unit	1641
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	AREX-P03-005

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
LAP	A10	4,940,670	7/10/90	Rhodes	
	A11	4,950,480	8/21/90	Barber et al.	
	A12	4,997,762	3/5/91	Hanna, Jr. et al.	
	A13	5,053,224	10/1/91	Koprowski et al.	
	A14	5,183,657	2/2/93	Buurman	
	A15	5,308,614	5/3/94	Hakomori	
	A16	5,194,254	3/16/93	Barber et al.	
	A17	5,389,530	2/14/95	Hakomori	
	A18	5,478,556	12/26/95	Elliott et al.	
	A19	5,500,215	3/19/96	Hakomori	
	A20	5,009,888	4/23/91	Dunn	
	A21	5,518,723	5/21/96	Devico et al.	
	A22	5,013,547	5/7/91	Sweet et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
LAP	B1	EP 0 153 871	9/4/85	Tse Wen Chang		
	B2	EP 0288082	4/22/88	Europe		
	B3	PCT/EP94/01719	8/12/94	PCT		
	B4	PCT/US90/03142	STAT	PCT		
	B5	PCT/US92/11334	7/8/93	PCT		
	B6	WO 89/01629	2/23/89	PCT		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LAP	C1	Abstract of Golumbek et al., Immunologic Research, 1993, pp. 183-192, Vol. 12.	
	C2	Abstract of Hilkens et al., Cancer Letters, 1995, pp. 27-33, Vol. 90.	
	C3	Baum et al., Hybridoma, 1993, pp. 583-589, Vol. 12.	
	C4	Baum et al., Cancer, 1994, pp. 1121-1125, Vol. 73.	
	C5	Chatterjee et al., Cancer Immunol Immunother, 1994, pp. 75-82, Vol. 38.	

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
-----------------------	----------------	--------------------	------------




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/824554
				Filing Date	April 14, 2004
				First Named Inventor	Ragupathy Madiyalakan
				Art Unit	1641
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	AREX-P03-005

40	C6	Colman, "Structure of Antibody-Antigen Complexes: Implications for Immune Recognition," Advances in Immunology, 1988, pp. 99-132, Vol. 43.
	C7	Ghiron et al., Photochemistry and Photobiology, 1968, pp. 87-92, Vol. 7.
	C8	Gura, Science, 1997, pp. 1041-1042, Vol. 278.
	C9	Herbert et al., Dictionary of Immunology, Academic Press, London, 1995, pp. 58; 59, 72, 73, and 154.
	C10	Imai et al., Acta Pathol, Japan, 1989, pp. 43-49, Vol. 29.
	C11	Jacobs et al., "Clinical Use of Tumor Markers in Oncology," Current Problems in Cancer, 1991, pp. 299-350.
	C12	Jose et al., Molecular Immunology, 1987, pp. 1145-1150, Vol. 24.
	C13	Kallenbach et al., Curr. Stud Hematol Blood Transfus, 1989, pp. 70-82.
	C14	Kehoe, S., International Journal of Oncology, 1995, pp. 451-458, Vol. 6.
	C15	Kleckowski et al., Photochem. Photobiol., 1962, pp. 299-304, Vol. 1.
	C16	Lanzavecchia, "Mechanisms of antigen uptake for presentation," Current Opinion in Immunology, 1996, pp. 348-354, Vol. 8.
	C17	Lanzavecchia, Science, 1993, pp. 937-944, Vol. 260.
	C18	Leoni et al., Int J Cancer, 1987, pp. 592-597, Vol. 40.
	C19	Madiyalakan et al., "OVAREX™ MAb-B43.13:IFN-γ Could Improve the Ovarian Tumor Cell Sensitivity to CA125-Specific Allogenic Cytotoxic T Cells," Hybridoma, 1997, pp. 41-45, Vol. 16.
	C20	Madiyalakan et al., Hybridoma, 1995, pp. 199-203, Vol. 14.
	C21	Murray et al., J.A.M.A., 1955, pp. 8-14.
	C22	Nemazee et al., PNAS, 1982, pp. 3828-3832, Vol. 79.
	C23	Noujaim et al., Current Tumor Diagnosis, 1994, pp. 823-829.
	C24	Prodouz et al., Blood, 1987, pp. 589-592, Vol. 70.
	C25	Simitsek et al., "Modulation of Antigen Processing by Bound Antibodies Can Boost or Suppress Class II Major Histocompatibility Complex Presentation of Different T Cell Determinants," Journal of Experimental Medicine, 1995, pp. 1957-1963, Vol. 181.
	C26	Stevenson et al., Immunol, 1994, pp. 16-19, Vol. 2.
	C27	Sykes et al., The Journal of Nuclear Medicine, 1995, pp. 1913-1922, Vol. 36.
↓	C28	Thomson et al., Clin Exp Immunol, 1994, pp. 351-357, Vol. 98.

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
--------------------	----------------	-----------------	------------



Substitute for Form 1449A/B/PTO				Complete If Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/824,554
				Filing Date	April 14, 2004
				First Named Inventor	Ragupathy Madiyalakan
				Art Unit	1641
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	AREX-P03-005


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
LAP	A23	5,240,833	Aug. 31, 1993	Nudelman et al.	
	A24	5,807,978	Sept. 15, 1998	Kokolus et al.	
	A25	6,088,613	July 11, 2000	Unger	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
LAP	B7	EP 315,456	05-1989	Fagani		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
-----------------------	----------------	--------------------	------------



sPTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/824,554
				Filing Date	April 14, 2004
				First Named Inventor	Ragupathy Madiyalakan
				Art Unit	1641
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	AREX-P03-005

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
LAB	AA	US-4,740,371	04-26-1988	St. Remy et al.	
	AB	US-4,879,225	11-07-1989	Morgan Jr. et al.	
	AC	US-5,512,283	04-30-1996	Byers et al.	
	AD	US-5,532,159	07-02-1996	Webb et al.	
	AE	US-5,583,202	12-10-1996	Zanetti	
	AF	US-5,591,593	01-07-1997	Courtenay-Luck	
	AG	US-5,652,114	07-29-1997	Chu et al.	
	AH	US-5,688,657	11-18-1997	Tsang et al.	
	AI	US-5,725,856	03-10-1998	Hudziak et al.	
	AJ	US-5,869,445	02-09-1999	Cheever et al.	
	AK	US-5,997,315	11-02-1999	Chatterjee et al.	
	AL	US-6,068,830	05-30-2000	Diamandis et al.	
	AM	US-6,077,519	06-20-2000	Storkus et al.	
	AN	US-6,140,091	10-31-2000	Raso et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
LAB	BA	WO 93/20185		10-14-1993	Steinman et al.		
	BB	WO 94/21287		09-29-1994	Berzofsky et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LAB	CA	Algarra et al., "Altered MHC class I antigens in tumors", Int. J. of Clin. & Lab, 27:95-102 (1997).	
	CB	Antonia et al., "Mechanisms of immune tolerance induction through the thymic expression of a peripheral tissue-specific protein", Int. Imm., 7:715-725 (1995).	
	CC	Bachmann et al., "Regulation of IgG antibody titers by the amount persisting of immune-complexed antigen," Eur. J. Imm., 24:2567-70 (1994).	
	CD	Baum et al., "Activating Anti-Idiotypic Human Anti-Mouse Antibodies for Immunotherapy of Ovarian Carcinoma", Cancer, 73:1121-25 (1994).	
	CE	Benichou et al., "Disruption of the determinant hierarchy on a self-MHC peptide: concomitant tolerance induction to the dominant determinant and priming to the cryptic self-determinant", Int. Imm., 6:131-38 (1994).	
	CF	Bodey et al., "Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy", Anticancer Res., 20:2665-2676 (2000).	
	CG	Chatopadhyay et al., "Human high molecular weight-melanoma associated antigen mimicry	

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
--------------------	----------------	-----------------	------------

3190902

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/824,554
				Filing Date	April 14, 2004
				First Named Inventor	Ragupathy Madiyalakan
				Art Unit	1641
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	AREX-P03-005

LAA		by an anti-idiotypic antibody: characterization of the immunogenicity and the immune response to the mouse monoclonal antibody IMel-1," Cancer Res., 5:6045-51 (1991).	
	CH	Cibotti, PNAS, "Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants", 89:416-20 (1992).	
	CI	Clark, "Protein Engineering of antibody Molecules for Prophylactic and therapeutic Applications in Man, (monograph), Prot. Eng., 1 (1993).	
	CJ	Crowley et al., "Dendritic cells are the principal cells in mouse spleen bearing immunogenic fragments of foreign proteins", J. Exp. Med., 172:383-386 (1990).	
	CK	De la Salle, "FcyR on Human Dendritic Cells", Human IgG Receptors, p. 39-55 (1996).	
LAA	CL	Fagerberg, "Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A," Cancer Imm., 12:81-87 (1996).	
	CM	Frodin et al., Hybridoma, "Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome--an important antitumoral effector function?," 10:421-31 (1991).	
	CN	Goldenberg et al., "Cancer Diagnosis and Therapy with Radiolabeled Antibodies", In: Immunoconjugates, Antibody Conjugates in Radioimaging and Therapy of Cancer, Vogel. Ed., 259-280 (1987).	
	CO	Jumic-Winkler, "Clinical evaluation of a new prostate-specific antigen sandwich ELISA which employs four monoclonal antibodies directed at different epitopes of prostate-specific antigen", Eur. Urol., 24:487-91 (1993).	
	CP	Keder et al., "Cancer Immunotherapy: Are the results discouraging? Can they be improved?", Adv. Cancer Res., 59:245-323 (1992).	
	CQ	Klaus, "Antigen-antibody complexes elicit anti-idiotypic antibodies to self-idiotopes," Nature, 272:265-66 (1978).	
	CR	Lee et al., "Increased Vaccine-Specific T Cell Frequency After Peptide-Based Vaccination Correlates with Increased Susceptibility to In Vitro Stimulation But Does Not Lead to Tumor Regression", J. Imm., 163:6292-300 (1999).	
	CS	Leitzel, "Elevated Soluble c-erbB-2 Antigen Levels in the Serum and Effusions of a Proportion of Breast Cancer Patients", J. Clin. Oncol., 10:1436-1442 (1992).	
	CT	McGuckin et al., "Circulating tumour-associated mucin concentrations, determined by the CASA assay, in healthy women," Clin. Chim. Acta, 214:139-51 (1993).	
	CU	Nishimura, "The critical role of TH1-dominant immunity in tumor immunology, Cancer Chemother", Cancer/Chemo, 46:S52-S61 (2000).	
	CV	Ohlen et al., "Expression of a Tolerizing Tumor Antigen in Peripheral Tissue Does Not Preclude Recovery of High-Affinity CB ^{HT} Cells of CTL Immunotherapy of Tumors Expressing the Antigen", J. Imm., 166:2863-2870 (2001).	
	CW	Pani et al., "Failure of presented, nondominant self epitope to induce tolerance - implications for autoimmune-diseases", Imm. Inv., 23:337-346 (1994).	
	CX	Paul, "Factors limiting effective tumor immunity", Fund. Imm., 1163-69 (1993).	
	CY	Rooijen, "The role of the FDC-retained immune complex network and its dynamics in the activity of germinal centres," Res. Immunol., 144:545-52 (1993).	
	CZ	Sallusto, "Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α ", J. Exp. Med., 179:1109-1118 (1994).	
	CA1	Schlom, In: Molecular foundations of Oncology, S. Broder, Ed., Mol. Fndns. Oncol., 105-107 (1991).	
	CB1	Schwartz, "Cancer Markers," In: Cancer: Principles and Practice of Clinical Oncology, 4 th Ed., 531-542 (1994).	
	CC1	Semino et al., "Heterogeneity of the alpha-interferon-mediated overexpression of class-I and class-II major histocompatibility complex molecules in primary cultured cancer cells", J. Biol. Regs., 7:99-105 (1993).	

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
--------------------	----------------	-----------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/824,554
				Filing Date	April 14, 2004
				First Named Inventor	Ragupathy Madiyalakan
				Art Unit	1641
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	AREX-P03-005

LAB	CD1	Tassi et al., "Immunogenicity of anti-idiotypic antibodies and of their F(ab') ₂ fragments," Imm. Letts., 27:39-44 (1991).	
	CE1	Vrba et al., "Carcinoembryonic antigen: evidence for multiple antigenic determinants and isoantigens", PNAS, 72:4602-06 (1975).	
	CF1	Ward, "Unconjugated antibodies for cancer therapy: lessons from the clinic" Cancer Treatment Rev., 23:305-319 (1997).	
	CG1	Watts et al., "Suppressive Effect of Antibody on Processing of T Cell Epitopes", J. Exp. Med., 178:1459-1463 (1993).	
	CH1	Yin et al., "Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer," Int. J. Cancer, 65-406-412 (1996).	
	CI1	Qi et al., "Induction of idiotypic network to anti-MUC-1 antibody in breast cancer", Proceedings of the American Association for Cancer Research Annual, 39:367 (1998).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
-----------------------	----------------	--------------------	------------